Report of the Director General to the 2018 WIPO Assemblies

Report of the Director General to the 2018 WIPO Assemblies
Author: World Intellectual Property Organization
Publisher: WIPO
Total Pages: 60
Release: 2018-09-24
Genre: Law
ISBN: 9280529684

This report is a presentation of the work accomplished by the Organization during the year that has passed since the last meeting of the WIPO Assemblies.

World Intellectual Property Indicators 2019

World Intellectual Property Indicators 2019
Author: World Intellectual Property Organization
Publisher: WIPO
Total Pages: 226
Release: 2019-10-15
Genre: Law
ISBN: 9280530941

This authoritative report analyzes IP activity around the globe. Drawing on 2018 filing, registration and renewals statistics from national and regional IP offices and WIPO, it covers patents, utility models, trademarks, industrial designs, microorganisms, plant variety protection and geographical indications. The report also draws on survey data and industry sources to give a picture of activity in the publishing industry.

Promoting Access to Medical Technologies and Innovation - Intersections between Public Health, Intellectual Property and Trade

Promoting Access to Medical Technologies and Innovation - Intersections between Public Health, Intellectual Property and Trade
Author: World Intellectual Property Organization
Publisher: WIPO
Total Pages: 259
Release: 2013
Genre: Law
ISBN: 9280523082

This study has emerged from an ongoing program of trilateral cooperation between WHO, WTO and WIPO. It responds to an increasing demand, particularly in developing countries, for strengthened capacity for informed policy-making in areas of intersection between health, trade and IP, focusing on access to and innovation of medicines and other medical technologies.

Report of the Director General to the 2019 WIPO Assemblies

Report of the Director General to the 2019 WIPO Assemblies
Author: World Intellectual Property Organization
Publisher: WIPO
Total Pages: 60
Release: 2019-09-30
Genre: Law
ISBN: 9280530658

This report is a presentation of the work accomplished by the Organization during the year that has passed since the last meeting of the WIPO Assemblies.

Annual financial report and financial statements 2018

Annual financial report and financial statements 2018
Author: World Intellectual Property Organization
Publisher: WIPO
Total Pages: 87
Release: 2020-03-12
Genre: Law
ISBN:

WIPO financial statements are submitted to its Assemblies of Member States in accordance with the Financial Regulations and Rules.

Report of the Director General to the 2017 WIPO Assemblies

Report of the Director General to the 2017 WIPO Assemblies
Author: World Intellectual Property Organization
Publisher: WIPO
Total Pages: 60
Release: 2017
Genre: Law
ISBN: 928052884X

This report is a presentation of the work accomplished by the Organization during the year that has passed since the last meeting of the WIPO Assemblies.

Vaccines, Medicines and COVID-19

Vaccines, Medicines and COVID-19
Author: Germán Velásquez
Publisher: Springer Nature
Total Pages: 129
Release: 2022-01-01
Genre: Medical
ISBN: 3030891259

This open access book is a collection of research papers on COVID-19 by Germán Velásquez from 2020 and early 2021 that help to answer the question: How can an agency like the World Health Organization (WHO) be given a stronger voice to exercise authority and leadership? The considerable health, economic and social challenges that the world faced at the beginning of 2020 with COVID-19 continued and worsened in many parts of the world in the second-half of 2020 and into 2021. Many of these countries and nations wanted to explore COVID-19 on their own, sometimes without listening to the main international health bodies such as WHO, an agency of the United Nations system with long-standing experience and vast knowledge at the global level and of which all countries in the world are members. In this single volume, the chapters present the progress of thinking and debate — particularly in relation to drugs and vaccines — that would enable a response to the COVID-19 pandemic or to subsequent crises that may arise. Among the topics covered: COVID-19 Vaccines: Between Ethics, Health and Economics Medicines and Intellectual Property: 10 Years of the WHO Global Strategy Re-thinking Global and Local Manufacturing of Medical Products After COVID-19 Rethinking R&D for Pharmaceutical Products After the Novel Coronavirus COVID-19 Shock Intellectual Property and Access to Medicines and Vaccines The World Health Organization Reforms in the Time of COVID-19 Vaccines, Medicines and COVID-19: How Can WHO Be Given a Stronger Voice? is essential reading for negotiators from the 194 member countries of the World Health Organization (WHO); World Trade Organization (WTO) and World Intellectual Property Organization (WIPO) staff participating in these negotiations; academics and students of public health, medicine, health sciences, law, sociology and political science; and intergovernmental organizations and non-governmental organizations that follow the issue of access to treatments and vaccines for COVID-19.

WHO guideline on country pharmaceutical pricing policies

WHO guideline on country pharmaceutical pricing policies
Author:
Publisher: World Health Organization
Total Pages: 70
Release: 2020-09-29
Genre: Business & Economics
ISBN: 9240011870

In recent years, high prices of pharmaceutical products have posed challenges in high- and low-income countries alike. In many instances, high prices of pharmaceutical products have led to significant financial hardship for individuals and negatively impacted on healthcare systems' ability to provide population-wide access to essential medicines. Pharmaceutical pricing policies need to be carefully planned, carried out, and regularly checked and revised according to changing conditions. Strong, well-thought-out policies can guide well-informed and balanced decisions to achieve affordable access to essential health products. This guideline replaces the 2015 WHO guideline on country pharmaceutical pricing policies, revised to reflect the growing body of literature since the last evidence review in 2010. This update also recognizes country experiences in managing the prices of pharmaceutical products.